Tiapride in levodopa-induced involuntary movements.
The effect of Tiapride on levodopa-induced hyperkinesia and on-off phenomena was evaluated in 13 patients with Parkinson's disease in a randomized dose-finding, double-blind placebo cross-over study. The patients were checked using a modified Webster rating scale; hyperkinesia were rated on a 0-3 points scale for 5 regions and on-off periods measured by duration and frequency. Tiapride in doses not accompanied by significant recurrence of Parkinsonian symptoms revealed no significant diminution of the involuntary movements, and no effect on on-off periods was found.
D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000503:physiopathology*; D011897:Random Allocation; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use*
D001549:Benzamides; D007980:Levodopa; D013976:Tiapamil Hydrochloride